<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DEZOCINE</span><br/>(de'zo-ceen)<br/><span class="topboxtradename">Dalgan<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">narcotic (opiate) agonist-antagonist</span>; <span class="classification">analgesic</span><br/><b>Prototype: </b>Pentazocine<br/><b>Pregnancy Category: </b>C<br/><b>Controlled Substance: </b>Schedule IV<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg/mL, 10 mg/mL, 15 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Dezocine is an agonistantagonist opioid. Because of its narcotic antagonist activity, dezocine may precipitate withdrawal
         symptoms in individuals with opiate dependence. Causes less respiratory depression and hypotension than morphine and no broncho-constrictive
         or histamine-releasing activity following its administration.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>It is comparable to morphine in analgesic potency, onset, and duration of action in the relief of postoperative pain.</p>
<h1><a name="uses">Uses</a></h1>
<p>Management of pain when the use of an opioid is appropriate.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to dezocine or structurally related drugs, concurrent use of CNS depressants; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>COPD, chronic bronchitis, emphysema, head injury, increased intracranial pressure, pregnancy (category C).</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle"></span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 2.510 mg (usually 5 mg) q24h <span class="rdroute">IM</span> 520 mg (usually 10 mg), may repeat q36h (max: 20 mg single dose; max: 120 mg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>Do not administer to anyone with a known sulfite allergy.</li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li> 					Note: 20 mg is the maximum single IM dose; 120 mg is the maximum daily IM dose. 				</li>
<li>Doses should be reduced for older adult patients and those with renal or hepatic insufficiency.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give by direct IV over 3060 s.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store at room temperature, 15°30° C (59°86° F), and protect from light. Do not use if precipitate
            is visible.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, dizziness, anxiety, euphoria, dysphoria, sedation.  <span class="typehead">CV:</span> Bradycardia, hypotension. <span class="typehead">GI:</span> <span class="speceff-common">Nausea, vomiting</span>. <span class="typehead">Respiratory:</span> Respiratory depression. <span class="typehead">Other:</span> Miosis, pruritus, mild itching, drug dependence. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">barbiturates</span>, other <span class="classification">opiates</span>, <span class="classification">inhalation general anesthetics</span>, and other <span class="classification">cns depressants</span> may enhance the cardiovascular and CNS effects; <span class="classification">monoamine oxidase inhibitors</span> should be avoided; increased respiratory depression when used with other <span class="classification">opioids</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Completely absorbed from IM site. <span class="typehead">Onset:</span> 1530 min. <span class="typehead">Peak:</span> 1090 min IM. <span class="typehead">Duration:</span> 46 h. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 2.6 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess for pain relief; onset occurs within 1530 min, with peak effect at 60 min. Effective analgesia usually lasts
            46 h.
         </li>
<li>Monitor for respiratory depression (especially with preexisting pulmonary disease), changes in BP and heart rate (especially
            hypotension and bradycardia), and excess CNS depression.
         </li>
<li>Supervise ambulation; drug may cause dizziness.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Use caution with position changes and walking; drug may cause hypotension and dizziness.</li>
<li>Do not drive or engage in other hazardous activities until response to drug is known.</li>
<li>Report adverse drug effects. A dosage reduction or change of drug may be warranted.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>